Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Head & Neck 1Gastrointestinal 1

Conditions

Stomach Neoplasms 1Sarcoma, Alveolar Soft Part 1Neoplasm Metastasis 1Head and Neck Neoplasms 1Esophageal Neoplasms 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Biliary Tract Neoplasms 1

Interventions

pembrolizumab 24Magnetic Resonance Spectroscopy 10Carboplatin 8Nivolumab 7Docetaxel 7Paclitaxel 6Gemcitabine 6Trastuzumab 5Taxes 5Injections 5Fluorouracil 5Fluorodeoxyglucose F18 5Drug Therapy 5Cyclophosphamide 5Cisplatin 5fludarabine 4X-Rays 4Specimen Handling 4Radiotherapy 4Psychiatric Rehabilitation 4Polymerase Chain Reaction 4Leucovorin 4durvalumab 3atezolizumab 3Surveys and Questionnaires 3Standard of Care 3Irinotecan 3Immunohistochemistry 3Gene Expression Profiling 3Early Intervention, Educational 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Esophageal Neoplasms × TAS-116 × Thoracic × Clear all
NCT04999761 2024-09-25

AB122 Platform Study

Taiho Pharmaceutical Co., Ltd.

Phase 1 Recruiting
917 enrolled
GastrointestinalHead & NeckSarcomaThoracic

Biliary Tract Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Head and Neck Neoplasms, Neoplasm Metastasis, Stomach Neoplasms, Colorectal Neoplasms, Sarcoma, Alveolar Soft Part

Data powered by HemOnc (CC BY 4.0) Colophon âš¡